QuidelOrtho (QDEL) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $13.91, +0.29% vs the prior close of $13.87.
- Volume 2.00M shares, 1.1x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
QDEL ends flat (+0.3%) to $13.91. Closed at $13.91, +0.29% vs the prior close of $13.87. Day range $13.65–$14.16, opened at $13.86.
QDEL daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — QDEL ends flat (+0.3%) to $13.91
- Closed at $13.91, +0.29% vs the prior close of $13.87. Day range $13.65–$14.16, opened at $13.86.
- Volume was 2.00M shares, 1.1x its 50-day average of 1.77M.
- Price is +7.7% vs its 50-day average ($12.91) and -19.4% vs its 200-day average ($17.26).
- 52-week range $9.92–$35.58; today's close sits at 16% of that range, 60.9% below the 52-week high.
Oct 14, 2026 — QDEL dips 1.6% to $13.87
- Closed at $13.87, -1.63% vs the prior close of $14.10. Day range $13.64–$14.65, opened at $13.90.
- Volume was 2.15M shares, 1.2x its 50-day average of 1.75M.
- Price is +6.8% vs its 50-day average ($12.98) and -20.0% vs its 200-day average ($17.34).
- 52-week range $9.92–$35.58; today's close sits at 15% of that range, 61.0% below the 52-week high.
Oct 13, 2026 — QDEL jumps 6.4% to $14.10, a 1-month high
- Closed at $14.10, +6.42% vs the prior close of $13.25. Day range $13.33–$14.61, opened at $13.40.
- Volume was 3.05M shares, 1.8x its 50-day average of 1.72M.
- Price is +8.0% vs its 50-day average ($13.06) and -19.1% vs its 200-day average ($17.42).
- 52-week range $9.92–$35.58; today's close sits at 16% of that range, 60.4% below the 52-week high.
Oct 12, 2026 — QDEL dips 1.3% to $13.25
- Closed at $13.25, -1.27% vs the prior close of $13.42. Day range $13.04–$13.50, opened at $13.44.
- Volume was 2.61M shares, 1.6x its 50-day average of 1.68M.
- Price is +0.9% vs its 50-day average ($13.13) and -24.3% vs its 200-day average ($17.49).
- 52-week range $9.92–$35.58; today's close sits at 13% of that range, 62.8% below the 52-week high.
Oct 9, 2026 — QDEL jumps 8.1% to $13.42, a 1-month high on 2.2x normal volume
- Closed at $13.42, +8.14% vs the prior close of $12.41. Day range $12.21–$13.63, opened at $12.52.
- Volume was 3.58M shares, 2.2x its 50-day average of 1.64M — unusually heavy trading.
- Price is +1.7% vs its 50-day average ($13.20) and -23.6% vs its 200-day average ($17.57).
- 52-week range $9.92–$35.58; today's close sits at 14% of that range, 62.3% below the 52-week high.
Oct 8, 2026 — QDEL rises 0.8% to $12.41
- Closed at $12.41, +0.81% vs the prior close of $12.31. Day range $11.72–$12.59, opened at $12.26.
- Volume was 2.52M shares, 1.6x its 50-day average of 1.61M.
- Price is -6.4% vs its 50-day average ($13.26) and -29.7% vs its 200-day average ($17.65).
- 52-week range $9.92–$35.58; today's close sits at 10% of that range, 65.1% below the 52-week high.
Oct 7, 2026 — QDEL dips 2.1% to $12.31
- Closed at $12.31, -2.07% vs the prior close of $12.57. Day range $11.83–$12.41, opened at $12.34.
- Volume was 2.46M shares, 1.6x its 50-day average of 1.58M.
- Price is -7.8% vs its 50-day average ($13.34) and -30.6% vs its 200-day average ($17.73).
- 52-week range $9.92–$35.58; today's close sits at 9% of that range, 65.4% below the 52-week high.
Oct 6, 2026 — QDEL jumps 3.5% to $12.57 on 2.1x normal volume
- Closed at $12.57, +3.54% vs the prior close of $12.14. Day range $12.15–$13.09, opened at $12.26.
- Volume was 3.22M shares, 2.1x its 50-day average of 1.54M — unusually heavy trading.
- Price is -6.4% vs its 50-day average ($13.43) and -29.4% vs its 200-day average ($17.81).
- 52-week range $9.92–$35.58; today's close sits at 10% of that range, 64.7% below the 52-week high.
- That makes 3 straight gains.
Oct 5, 2026 — QDEL jumps 12.7% to $12.14
- Closed at $12.14, +12.72% vs the prior close of $10.77. Day range $10.52–$12.51, opened at $10.86.
- Volume was 2.69M shares, 1.8x its 50-day average of 1.50M.
- Price is -10.2% vs its 50-day average ($13.52) and -32.2% vs its 200-day average ($17.90).
- 52-week range $9.92–$35.58; today's close sits at 9% of that range, 65.9% below the 52-week high.
Oct 2, 2026 — QDEL jumps 3.8% to $10.77
- Closed at $10.77, +3.76% vs the prior close of $10.38. Day range $10.46–$11.18, opened at $10.67.
- Volume was 2.42M shares, 1.6x its 50-day average of 1.47M.
- Price is -20.8% vs its 50-day average ($13.60) and -40.1% vs its 200-day average ($17.98).
- 52-week range $9.92–$35.58; today's close sits at 3% of that range, 69.7% below the 52-week high.
QDEL latest news & SEC filings
Every SEC filing by or about QDEL in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 7, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 23, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
Sep 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Bowman Ronald Lee converted options/RSUs into 2,566 shares on Sep 15, 2026; now holds 5,941
- Bowman Ronald Lee had withheld for taxes 921 shares at $10.63 (≈$9.79K) on Sep 15, 2026; now holds 5,020
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 7, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 28, 2026:
- Revenue: $630.90M (prior year $613.90M) (+2.8% vs Jun 29, 2025)
- Net income: -$92.90M (prior year -$255.40M) (loss narrowed vs Jun 29, 2025)
- Diluted EPS: -$1.36 (prior year -$3.77) (loss narrowed vs Jun 29, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 5, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 16, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 15, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Jul 13, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Jul 8, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Things to know before you trade QDEL
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 5, 2026, Apr 15, 2026, Feb 11, 2026. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.21% (largest 12.7%). That is a volatile stock.
- Liquidity: about 2.08M shares (≈$28.95M) trade per day on average.
- 52-week position: $13.91 vs a range of $9.92–$35.58 (16% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 9 open-market buys, 1 sales; latest: Joseph M. Busky bought 3,370 shares on Feb 13, 2026.
- Latest filings: 8-K Sep 23, 2026; 10-Q Aug 7, 2026; 8-K Aug 6, 2026.
- Share count: 68.58M shares outstanding (Jul 29, 2026), +1.0% vs a year earlier.
- Listing: Nasdaq · industry: In Vitro & In Vivo Diagnostic Substances.
QDEL market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 13.86 | 14.16 | 13.65 | 13.91 | 2.00M |
| Oct 14, 2026 | 13.90 | 14.65 | 13.64 | 13.87 | 2.15M |
| Oct 13, 2026 | 13.40 | 14.61 | 13.33 | 14.10 | 3.05M |
| Oct 12, 2026 | 13.44 | 13.50 | 13.04 | 13.25 | 2.61M |
| Oct 9, 2026 | 12.52 | 13.63 | 12.21 | 13.42 | 3.58M |
| Oct 8, 2026 | 12.26 | 12.59 | 11.72 | 12.41 | 2.52M |
| Oct 7, 2026 | 12.34 | 12.41 | 11.83 | 12.31 | 2.46M |
| Oct 6, 2026 | 12.26 | 13.09 | 12.15 | 12.57 | 3.22M |
| Oct 5, 2026 | 10.86 | 12.51 | 10.52 | 12.14 | 2.69M |
| Oct 2, 2026 | 10.67 | 11.18 | 10.46 | 10.77 | 2.42M |
| Oct 1, 2026 | 10.55 | 10.64 | 9.93 | 10.38 | 2.77M |
| Sep 30, 2026 | 10.64 | 10.64 | 10.34 | 10.54 | 1.38M |
| Sep 29, 2026 | 10.89 | 10.95 | 10.50 | 10.60 | 895.50K |
| Sep 28, 2026 | 10.94 | 11.10 | 10.68 | 10.83 | 760.00K |
| Sep 25, 2026 | 10.69 | 10.95 | 10.42 | 10.94 | 1.38M |
| Sep 24, 2026 | 10.35 | 10.93 | 10.35 | 10.69 | 1.44M |
| Sep 23, 2026 | 10.92 | 11.10 | 10.32 | 10.34 | 1.11M |
| Sep 22, 2026 | 10.86 | 11.15 | 10.80 | 10.94 | 1.15M |
| Sep 21, 2026 | 10.78 | 10.97 | 10.40 | 10.86 | 1.07M |
| Sep 18, 2026 | 11.00 | 11.09 | 10.36 | 10.62 | 2.98M |
About QuidelOrtho
QuidelOrtho (QDEL) is listed on the Nasdaq and classified by the SEC under “In Vitro & In Vivo Diagnostic Substances”. Its business address is in SAN DIEGO, CA. Fiscal year ends January 1. SEC CIK 1906324.
QDEL board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Kenneth F Buechler | Director | Jun 29, 2026 |
| John R Chiminski | Director | Jun 29, 2026 |
| Evelyn S Dilsaver | Director | Jun 29, 2026 |
| R Scott Huennekens | Director | Jun 29, 2026 |
| Edward L. Michael | Director | Jun 29, 2026 |
| Mary Lake Ph D Polan | Director | Jun 29, 2026 |
| Ann D Rhoads | Director | Jun 29, 2026 |
| Matthew Strobeck | Director | Jun 2, 2026 |
| Kenneth J Widder | Director | Jun 29, 2026 |
| Joseph D Jr. Wilkins | Director | Jun 29, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Brian J. Blaser | President and CEO | May 19, 2026 |
| Ronald Lee Bowman | Chief Human Resources Officer | Sep 17, 2026 |
| Joseph M. Busky | Chief Financial Officer | Mar 31, 2026 |
| Bryan Michael Hanson | EVP Global Port. Mgmt & Mkting | Aug 18, 2026 |
| Michelle A Hodges | Chief Legal Officer | Feb 10, 2026 |
| Philip D. Mclellan | Chief Operations Officer | Apr 28, 2026 |
| Nathaniel Sisitsky | Chief Legal Officer | Apr 22, 2026 |
| Jonathan Philip Siegrist | EVP of R&D & CTO | Feb 3, 2026 |
| Micah W Young | Chief Financial Officer | Jul 16, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Feb 13, 2026 | Joseph M. Busky | Buy | 3,370 | $23.66 |
| Feb 13, 2026 | Matthew Strobeck | Buy | 10,000 | $23.96 |
| Feb 13, 2026 | Brian J. Blaser | Buy | 10,540 | $23.59 |
| Feb 13, 2026 | Joseph M. Busky | Buy | 3,370 | $23.66 |
| Dec 10, 2025 | Ann D Rhoads | Buy | 750 | $28.28 |
| Nov 26, 2025 | Joseph D Jr. Wilkins | Buy | 370 | $27.96 |
| Nov 25, 2025 | Kenneth J Widder | Sale | 4,026 | $27.81 |
| Nov 24, 2025 | Joseph M. Busky | Buy | 4,770 | $26.06 |
| Nov 21, 2025 | Mary Lake Ph D Polan | Buy | 1,000 | $22.43 |
| Nov 19, 2025 | Brian J. Blaser | Buy | 23,500 | $21.34 |
QDEL financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 28, 2025 | $2.73B | $-1.13B | -16.69 | $105.20M |
| Dec 29, 2024 | $2.78B | $-2.05B | -30.54 | $83.00M |
| Dec 31, 2023 | $3.00B | $-10.10M | -0.15 | $280.20M |
| Jan 1, 2023 | $3.27B | $548.70M | 9.56 | $885.30M |
| Jan 2, 2022 | $1.70B | $704.20M | 16.43 | $805.90M |
Latest balance sheet: total assets $5.72B, total liabilities $3.94B, cash $123.40M (as of Jun 28, 2026).
QDEL earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $16.32 |
| May 5, 2026 | 8-K Item 2.02 (results) | $11.66 |
| Apr 15, 2026 | 8-K Item 2.02 (results) | $17.49 |
| Feb 11, 2026 | 8-K Item 2.02 (results) | $28.80 |
| Nov 5, 2025 | 8-K Item 2.02 (results) | $27.37 |
| Aug 5, 2025 | 8-K Item 2.02 (results) | $23.68 |
| May 7, 2025 | 8-K Item 2.02 (results) | $25.85 |
| Feb 12, 2025 | 8-K Item 2.02 (results) | $39.94 |
| Jan 13, 2025 | 8-K Item 2.02 (results) | $44.61 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $38.85 |
| Jul 31, 2024 | 8-K Item 2.02 (results) | — |
| May 8, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · In Vitro & In Vivo Diagnostic Substances
Idexx Laboratories (IDXX)Lantheus (LNTH)Intellia Therapeutics (NTLA)Neogen (NEOG)Celldex Therapeutics (CLDX)Achieve Life Sciences (ACHV)Myriad Genetics (MYGN)Alpha Teknova (TKNO)Insight Molecular Diagnostics (IMDX)Volitionrx (VNRX)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on QDEL
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.